{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:50:07Z","timestamp":1793213407730,"version":"4.5.0"},"reference-count":30,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Natural Science Foundation of China (Youth Program)","award":["82102831"],"award-info":[{"award-number":["82102831"]}]},{"name":"National Natural Science Foundation of China (Youth Program)","award":["YNRCQN0302"],"award-info":[{"award-number":["YNRCQN0302"]}]},{"name":"National Natural Science Foundation of China (Youth Program)","award":["KD2023KYJJ265"],"award-info":[{"award-number":["KD2023KYJJ265"]}]},{"name":"Talent Special Fund of the First Affiliated Hospital of Nanjing Medical University","award":["82102831"],"award-info":[{"award-number":["82102831"]}]},{"name":"Talent Special Fund of the First Affiliated Hospital of Nanjing Medical University","award":["YNRCQN0302"],"award-info":[{"award-number":["YNRCQN0302"]}]},{"name":"Talent Special Fund of the First Affiliated Hospital of Nanjing Medical University","award":["KD2023KYJJ265"],"award-info":[{"award-number":["KD2023KYJJ265"]}]},{"name":"Science Foundation of Kangda College of Nanjing Medical University","award":["82102831"],"award-info":[{"award-number":["82102831"]}]},{"name":"Science Foundation of Kangda College of Nanjing Medical University","award":["YNRCQN0302"],"award-info":[{"award-number":["YNRCQN0302"]}]},{"name":"Science Foundation of Kangda College of Nanjing Medical University","award":["KD2023KYJJ265"],"award-info":[{"award-number":["KD2023KYJJ265"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>This study aims to evaluate the clinical effectiveness of trilaciclib in preventing myelosuppression in patients with esophageal cancer undergoing chemotherapy. Based on the use of trilaciclib, 81 patients were divided into a primary prevention group (PP group, n = 49) and a secondary prevention group (SP group, n = 32). The incidence of myelosuppression, antibiotic usage rate, survival outcomes, and other treatment-related toxicities were analyzed using chi-square tests and Kaplan\u2013Meier survival curves. The incidence of chemotherapy-induced myelosuppression in the SP group was significantly higher than that in the PP group (96.9% vs. 79.6%), with a significantly higher proportion of grade III and above events (37.6% vs. 8.2%, p &lt; 0.05). For chemotherapy-induced neutropenia, the incidence of grade III\/IV events in the SP group was significantly higher than in the PP group (28.1% vs. 8.2%, p = 0.017). Additionally, the SP group experienced higher rates and severity of chemotherapy-induced anemia and thrombocytopenia. The PP group provided better protection against grade III\/IV leukopenia and neutropenia (p &lt; 0.05). Non-hematological toxicities and efficacy outcomes were similar between groups (p &gt; 0.05). The study is the first to demonstrate that trilaciclib is a safe and effective option for the prevention of myelosuppression in esophageal cancer patients.<\/jats:p>","DOI":"10.3390\/curroncol32040189","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T06:21:38Z","timestamp":1742797298000},"page":"189","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Clinical Outcomes of Trilaciclib for the Prevention of Myelosuppression in Patients with Esophageal Cancer Undergoing Chemotherapy"],"prefix":"10.3390","volume":"32","author":[{"given":"Hui","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingze","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 211199, China"},{"name":"Department of Oncology, Kangda College of Nanjing Medical University, Nanjing 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchen","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1007\/s12328-020-01237-x","article-title":"Epidemiology of esophageal cancer: Update in global trends, etiology and risk factors","volume":"13","author":"Uhlenhopp","year":"2020","journal-title":"Clin. J. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/dote.12088","article-title":"Esophageal squamous cell carcinoma (ESCC): Advance in genomics and molecular genetics","volume":"28","author":"Chen","year":"2015","journal-title":"Dis. Esophagus"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jare.2022.10.007","article-title":"Global burden and temporal trends in incidence and mortality of oesophageal cancer","volume":"50","author":"Zhou","year":"2023","journal-title":"J. Adv. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"855","DOI":"10.6004\/jnccn.2019.0033","article-title":"Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Ajani","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Barsouk, A., Rawla, P., Hadjinicolaou, A.V., Aluru, J.S., and Barsouk, A. (2019). Targeted Therapies and Immunotherapies in the Treatment of Esophageal Cancers. Med. Sci., 7.","DOI":"10.3390\/medsci7100100"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1245\/s10434-024-16196-7","article-title":"Safety and Efficacy of Conversion Therapy After Systemic Chemotherapy in Advanced Esophageal Cancer with Distant Metastases: A Multicenter Retrospective Observational Study","volume":"32","author":"Tsuji","year":"2025","journal-title":"Ann. Surg. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Wang, J., Zhang, K., Liu, T., Song, Y., Hua, P., Chen, S., Li, J., Liu, Y., and Zhao, Y. (2022). Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced esophageal cancer: A meta-analysis. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.974684"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Wang, H., Xu, Y., Zuo, F., Liu, J., and Yang, J. (2022). Immune-based combination therapy for esophageal cancer. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1020290"},{"key":"ref_9","unstructured":"Shen, B., and Han, Z. (2023). Survey Report on the Current Status of Myelosuppression and Clinical Management in Chinese Cancer Chemotherapy, Southeast University Press."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1007\/s12325-020-01419-6","article-title":"Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors","volume":"37","author":"Epstein","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"10732748221126929","DOI":"10.1177\/10732748221126929","article-title":"Predictive Model of Chemotherapy-Induced Myelosuppression for Patients with Esophageal Cancer","volume":"29","author":"Zheng","year":"2022","journal-title":"Cancer Control"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1053\/j.seminoncol.2005.11.003","article-title":"Myelotoxicity from chemotherapy","volume":"33","author":"Daniel","year":"2006","journal-title":"Semin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.2217\/fon-2020-1191","article-title":"Polymorphism of FGD4 and myelosuppression in patients with esophageal squamous cell carcinoma","volume":"17","author":"Yang","year":"2021","journal-title":"Future Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cllc.2021.03.010","article-title":"Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies","volume":"22","author":"Weiss","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1158\/1535-7163.MCT-15-0775","article-title":"Preclinical Characterization of G1T28: A Novel CDK4\/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression","volume":"15","author":"Bisi","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s40265-021-01508-y","article-title":"Trilaciclib: First Approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e000847","DOI":"10.1136\/jitc-2020-000847","article-title":"CDK4\/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy","volume":"8","author":"Lai","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.2217\/fon-2022-0773","article-title":"Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: Phase III PRESERVE 2","volume":"18","author":"Goel","year":"2022","journal-title":"Future Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S1470-2045(19)30616-3","article-title":"Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: A multicentre, randomised, open-label, phase 2 trial","volume":"20","author":"Tan","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ccell.2022.02.007","article-title":"Toripalimab plus chemotherapy in treatment-na\u00efve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial","volume":"40","author":"Wang","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_22","unstructured":"Expert Committee of Integrated Chinese and Western Medicine (2021). Expert consensus on the diagnosis and treatment of bone marrow suppression caused by antitumor drugs with integrated traditional Chinese and Western medicine. Chin. J. Clin. Oncol., 26, 1020\u20131027."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/17512433.2021.1884067","article-title":"Treatment of infections in cancer patients: An update from the neutropenia, infection and myelosuppression study group of the Multinational Association for Supportive Care in Cancer (MASCC)","volume":"14","author":"Rapoport","year":"2021","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.2217\/fon-2022-0754","article-title":"Burden of chemotherapy-induced myelosuppression among patients with ES-SCLC in US community oncology settings","volume":"18","author":"Goldschmidt","year":"2022","journal-title":"Future Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/annonc\/mdz278","article-title":"Myelopreservation with the CDK4\/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: A phase Ib\/randomized phase II trial","volume":"30","author":"Weiss","year":"2019","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","article-title":"CDK4\/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation","volume":"8","author":"Deng","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1002\/ijc.33453","article-title":"Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial","volume":"148","author":"Daniel","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1158\/1078-0432.CCR-21-2272","article-title":"Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study","volume":"28","author":"Tan","year":"2022","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1038\/s41401-024-01297-6","article-title":"Trilaciclib dosage in Chinese patients with extensive-stage small cell lung cancer: A pooled pharmacometrics analysis","volume":"45","author":"Dai","year":"2024","journal-title":"Acta Pharmacol. Sin."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/4\/189\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:58:58Z","timestamp":1760029138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/4\/189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["curroncol32040189"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32040189","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,24]]}}}